OTCMKTS:DDXS

(DDXS) Stock Forecast, Price & News

$0.0001

0.00 (0.00 %)

(As of 12/7/2020)

Add

Compare

Today's Range

$0.00

Now: $0.00▼

$0.00

50-Day Range N/A

52-Week Range

$0.01

Now: $0.00▼

$5.40

Volume30 shs

Average Volume15,481 shs

Market Capitalization$410.00

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.

MarketRank^™

Overall MarketRank^™

0.52 out of 5 stars

Health Technology Sector

9th out of 18 stocks

Biotechnology Industry

43rd out of 88 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for (DDXS).

2.6 Community Rank

Outperform Votes
(DDXS) has received 137 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
(DDXS) has received 130 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
(DDXS) has received 51.31% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about (DDXS) and other stocks. Vote “Outperform” if you believe DDXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
(DDXS) does not currently pay a dividend.
Dividend Growth
(DDXS) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, (DDXS) insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biotechnology

Sub-IndustryN/A

SectorHealth Technology

Current SymbolOTCMKTS:DDXS

Previous Symbol

CUSIP25245P106

CIK1036968

Webwww.diadexus.com

Phone(650) 246-6400

EmployeesN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares4,100,000

Market Cap$410.00

Next Earnings DateN/A

OptionableNot Optionable

$0.0001

0.00 (0.00 %)

(As of 12/7/2020)

30 days | 90 days | 365 days | Advanced Chart

Receive DDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for DDXS and its competitors with MarketBeat's FREE daily newsletter.

(DDXS) (OTCMKTS:DDXS) Frequently Asked Questions

What stocks does MarketBeat like better than (DDXS)?

Wall Street analysts have given (DDXS) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (DDXS) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were (DDXS)'s earnings last quarter?

(DDXS) (OTCMKTS:DDXS) released its quarterly earnings results on Monday, October, 26th. The company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.35.
View (DDXS)'s earnings history.

Who are some of (DDXS)'s key competitors?

Some companies that are related to (DDXS) include (CHV) (CHV), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of DDXS's competitors.

What other stocks do shareholders of (DDXS) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (DDXS) investors own include GoPro (GPRO), General Electric (GE), Ambarella (AMBA) and Alliqua Biomedical (ALQA).

Who are (DDXS)'s key executives?

(DDXS)'s management team includes the following people:

Kenneth Charles Fang, Chief Medical Officer
Amy Figueroa, Head-Investor Relations

What is (DDXS)'s stock symbol?

(DDXS) trades on the OTCMKTS under the ticker symbol "DDXS."

How do I buy shares of (DDXS)?

Shares of DDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is (DDXS)'s stock price today?

One share of DDXS stock can currently be purchased for approximately $0.00.

How big of a company is (DDXS)?

(DDXS) has a market capitalization of $410.00.

What is (DDXS)'s official website?

The official website for (DDXS) is www.diadexus.com.

How can I contact (DDXS)?

(DDXS)'s mailing address is 349 Oyster Point Blvd, SOUTH SAN FRANCISCO, CA 94080-1947, United States. The company can be reached via phone at (650) 246-6400.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here